Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Q4 2022 Earnings Presentation
11 slides from Genedx's earnings presentation, Mar 14, 2023
Slide 1: 4Q and Year End 2022 Earnings Presentation
March 14, 2023 One Test: Miss Less. Discover More. GeneDx (Nasdaq: WGS) 4Q and Year End 2022 Earnings Presentation
Slide 2: Disclaimer
2 Disclaimer This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, fo
Slide 3: Our mission: deliver personalized and actionable health insights
Our mission: deliver personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery.
Slide 4: The problem: lack of genomic data and connectivity with EMR
The problem: lack of genomic data and connectivity with EMR Symptoms Tests are ordered More tests But no answers Try new doctors But no records Suboptimal care Waiting for answers that come too late Patients miss milestones Waiting for a proper diagnosis More tests And more spending Years of missed
Slide 5: Our Solution: Genomic Data + Clinical Insights = Better Health
Our Solution: Genomic Data + Clinical Insights = Better Health
Slide 6: Built by GeneDx: Genomic interpretation platform
>400K clinical exomes > 1 million DNA extractions >400 gene discovery publications Built by GeneDx: Genomic interpretation platform Since our inception more than 20 years ago, we believe we offer the most definitive genomic analysis in the industry, borne from over a decade of constructing our propr
Slide 7: Built by Sema4: Centrellis health insights platform
Built by Sema4: Centrellis health insights platform We’ve spent over 10 years developing the most sophisticated dataset in the industry, complete with custom algorithms and more accurate analyses 3.1 million patient health records 8 million disease diagnoses 47 million phenotypes 20 years of records
Slide 8: Best of both creates a seamless solution
Best of both creates a seamless solution Sequence once Expand the use of and deliver best in class whole exome/genome analysis & interpretation Combine clinical + genomic data Match structured clinical and genomic data and supplement with disease models to drive insights Providing actionable insight
Slide 9: 4Q 2022 and Recent Highlights
4Q 2022 and Recent Highlights 9 Completed strategic shift to focus on scalable business and profitable growth $138.2M in cash, cash equivalents and restricted cash as of 12/31/22; fully funded to expected profitability in 2025 Completed financing in January 2023 with $150 million in expected proceed
Slide 10: Strong Momentum Across Pro Forma Legacy GeneDx Volume & Revenue
Strong Momentum Across Pro Forma Legacy GeneDx Volume & Revenue 10 Full Year 2022 Volume Mix Full Year 2022 Revenue Mix1 ~49k tests Q4 total volume +26% YoY1 7,862 Q4 Whole Exome / Whole Genome tests +19% YoY $45.8M Q4 total revenue +31% YoY1 $171.0M 2022 total revenue 39% adj gross margin $171.0M 2
Slide 11: 2023 Guidance
v Revenues between $205-220 million for full year 2023 Expanded adjusted gross margin profile 2023 and beyond Inclusive of servicing obligations of the exited business activities, total cash burn in 2023 between $130-145 million, a >50% reduction year-over-year Use of net $95-110 million in cash in